Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features

Hitoshi Dejima(The University of Texas MD Anderson Cancer Center), Xin Hu(The University of Texas MD Anderson Cancer Center), Runzhe Chen(The University of Texas MD Anderson Cancer Center), Jiexin Zhang(The University of Texas MD Anderson Cancer Center), Junya Fujimoto(The University of Texas MD Anderson Cancer Center), Edwin R. Parra(The University of Texas MD Anderson Cancer Center), Cara Haymaker(The University of Texas MD Anderson Cancer Center), Shawna M. Hubert(The University of Texas MD Anderson Cancer Center), Dzifa Y. Duose(The University of Texas MD Anderson Cancer Center), Luisa M. Solis(The University of Texas MD Anderson Cancer Center), Dan Su(Chinese Academy of Sciences), Junya Fukuoka(Kagoshima University), Kazuhiro Tabata(Kagoshima University), Hoa Pham(Nagasaki University), Nicholas McGranahan(CRUK Lung Cancer Centre of Excellence), Baili Zhang(The University of Texas MD Anderson Cancer Center), Jie Ye(The University of Texas MD Anderson Cancer Center), Lisha Ying(Chinese Academy of Sciences), Latasha Little(The University of Texas MD Anderson Cancer Center), Curtis Gumbs(The University of Texas MD Anderson Cancer Center), Chi‐Wan Chow(The University of Texas MD Anderson Cancer Center), Marcos R. Estecio(The University of Texas MD Anderson Cancer Center), Myrna C. B. Godoy(The University of Texas MD Anderson Cancer Center), Mara B. Antonoff(The University of Texas MD Anderson Cancer Center), Boris Sepesi(The University of Texas MD Anderson Cancer Center), Harvey I. Pass(NYU Langone Health), Carmen Behrens(The University of Texas MD Anderson Cancer Center), Jianhua Zhang(The University of Texas MD Anderson Cancer Center), Ara A. Vaporciyan(The University of Texas MD Anderson Cancer Center), John V. Heymach(The University of Texas MD Anderson Cancer Center), Paul Scheet(The University of Texas MD Anderson Cancer Center), J. Jack Lee(The University of Texas MD Anderson Cancer Center), Jia Wu(The University of Texas MD Anderson Cancer Center), P. Andrew Futreal(The University of Texas MD Anderson Cancer Center), Alexandre Reuben(The University of Texas MD Anderson Cancer Center), Humam Kadara(The University of Texas MD Anderson Cancer Center), Ignacio I. Wistuba(The University of Texas MD Anderson Cancer Center), Jianjun Zhang(The University of Texas MD Anderson Cancer Center)
Nature Communications
May 11, 2021
Cited by 139Open Access
Full Text

Abstract

The mechanism by which anti-cancer immunity shapes early carcinogenesis of lung adenocarcinoma (ADC) is unknown. In this study, we characterize the immune contexture of invasive lung ADC and its precursors by transcriptomic immune profiling, T cell receptor (TCR) sequencing and multiplex immunofluorescence (mIF). Our results demonstrate that anti-tumor immunity evolved as a continuum from lung preneoplasia, to preinvasive ADC, minimally-invasive ADC and frankly invasive lung ADC with a gradually less effective and more intensively regulated immune response including down-regulation of immune-activation pathways, up-regulation of immunosuppressive pathways, lower infiltration of cytotoxic T cells (CTLs) and anti-tumor helper T cells (Th), higher infiltration of regulatory T cells (Tregs), decreased T cell clonality, and lower frequencies of top T cell clones in later-stages. Driver mutations, chromosomal copy number aberrations (CNAs) and aberrant DNA methylation may collectively impinge host immune responses and facilitate immune evasion, promoting the outgrowth of fit subclones in preneoplasia into dominant clones in invasive ADC.


Related Papers

No related papers found

Powered by citation graph analysis